Results 281 to 290 of about 199,597 (317)

Long-Term Complete Response to Pembrolizumab in Tumor Mutation Burden-High Small Cell Lung Cancer: A Case Report. [PDF]

Case Rep Oncol
Komuta K, Kunimasa K, Miyazaki A, Futamura S, Tanaka T, Kawamura T, Inoue T, Tamiya M, Nishino K.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tumor mutational burden and immunotherapy in gliomas

Trends in Cancer, 2021
Tumor mutational burden (TMB) is an emerging biomarker for the prediction of immunotherapy success in solid tumors. Gliomas, however, do not demonstrate a correlation between TMB and immunotherapy efficacy. Here, we discuss the potential factors influencing this discordance, focusing on the impact of neoantigen immunogenicity, clonality, expression ...
Mythili Merchant, Alice Ranjan, Ying Pang, Guangyang Yu, Olga Kim, Javed Khan, Jing Wu   +6 more
openaire   +2 more sources

Tumor Mutational Burden Testing in Solid Tumors

JAMA Oncology, 2023
A 58-year-old man with diabetes, chronic kidney disease, and JAK2-positive myeloproliferative neoplasm is referred for newly diagnosed oligometastatic prostate cancer with substantial urinary symptoms. What would you do next?
Regina, Kwon, Heather H, Cheng, Colin C, Pritchard   +2 more
openaire   +2 more sources

Peritumoral Edema Correlates with Mutational Burden in Meningiomas

Neurosurgery, 2020
Meningiomas are the most common primary central nervous system tumor. Emerging data supports that higher mutational burden portends worse clinical outcomes in meningiomas. However, there is a lack of imaging biomarkers that are associated with tumor genomics in meningiomas.We performed next-generation targeted sequencing in a cohort of 75 primary ...
Corey M. Gill, Joshua Loewenstern, John W. Rutland, Hanane Arib, Margaret Pain, Melissa Umphlett, Yayoi Kinoshita, Russell B. McBride, Joshua Bederson, Michael Donovan, Robert Sebra, Mary Fowkes, Raj K. Shrivastava   +12 more
openaire   +2 more sources

The mutational burden of aging

Science, 2018
Genetics As people age, they accumulate somatic mutations in healthy cells. About 25% of cells in normal, sun-exposed skin harbor cancer driver mutations. What about tissues not exposed to powerful mutagens like ultraviolet light? Martincorena et al. performed targeted gene sequencing of normal esophageal epithelium from nine human donors of varying ...
openaire   +1 more source

The status of tumor mutational burden and immunotherapy

Nature Cancer, 2022
Valsamo, Anagnostou, Alberto, Bardelli, Timothy A, Chan, Samra, Turajlic   +3 more
openaire   +2 more sources

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Annals of Oncology, 2021
M Kok, Mustafa Khasraw, Bora Lim
exaly  

Tumor mutational burden

Cancer Cytopathology, 2019
openaire   +2 more sources

[Importance of tumour mutation burden testing].

Der Pathologe, 2020
Although therapy with immune checkpoint inhibitors (ICIs) for patients with non-small-cell lung carcinoma (NSCLC), which has recently become available, does offer a survival advantage compared with chemotherapy, the overall response rate is only around 20 %.
openaire   +1 more source

Lung Cancer with a High Tumor Mutational Burden

New England Journal of Medicine, 2018
Paul A, VanderLaan, Deepa, Rangachari, Daniel B, Costa   +2 more
openaire   +3 more sources